THREE INVESTIGATORS were named recipients of the 2015 Paul Marks Prize for Cancer Research by Memorial Sloan Kettering Cancer Center. The award recognizes investigators age 45 or younger for their efforts in advancing cancer research.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
